Commercial Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

Commercial When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

Legal/Regulatory Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.

Commercial If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

"In Australia, we are the healthcare industry," he says.

Data/Analytics Infographic: Can pharma give doctors what they want?

Infographic: Can pharma give doctors what they want?

Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?

Commercial Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

Therapeutic Focus For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Commercial When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Technology Japanese drugmakers lead the way in digital innovation

Japanese drugmakers lead the way in digital innovation

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

Features Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Data/Analytics Big data expert Hilary Mason on 3 ways to create a data-driven culture

Big data expert Hilary Mason on 3 ways to create a data-driven culture

The first step is to seek leadership support, she says.

Data/Analytics Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

Data/Analytics Pharma adopts data-science culture in move toward AI

Pharma adopts data-science culture in move toward AI

Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.

Features Read the complete December 2016 digital edition

Read the complete December 2016 digital edition

Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.

Pipeline The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Commercial The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Commercial Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Legal/Regulatory Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Commercial Infographic: what information doctors need from pharma

Infographic: what information doctors need from pharma

How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information

Campaigns Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Technology 3 health tech innovations experts say will revolutionalize healthcare

3 health tech innovations experts say will revolutionalize healthcare

As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.

Commercial Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

Features

Health Influencer 50: No. 1

Features

Health Influencer 50: No. 2

Features

Health Influencer 50: No. 3

Features

Health Influencer 50: No. 4

Features

Health Influencer 50: No. 5

Features

Health Influencer 50: No. 6

Features

Health Influencer 50: No. 7

Features

Health Influencer 50: No. 8

Features

Health Influencer 50: No. 9

Features

Health Influencer 50: No. 10

Features Health Influencer 50: 20-11

Health Influencer 50: 20-11

Features Health Influencer 50: 30-21

Health Influencer 50: 30-21

Features Health Influencer 50: 40-31

Health Influencer 50: 40-31

Features Health Influencer 50: 50-41

Health Influencer 50: 50-41

Features Health Influencer 50

Health Influencer 50

MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list.

Features Read the complete October 2016 digital edition

Read the complete October 2016 digital edition

Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.

Pipeline If Roche's Ocrevus is approved, the already competitive MS market will gain another player

If Roche's Ocrevus is approved, the already competitive MS market will gain another player

The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.

Commercial Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.

Pipeline New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

People Moves EMD Serono promotes Craig Millian to SVP of neurology and immunology

EMD Serono promotes Craig Millian to SVP of neurology and immunology

Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.

Careers Carling's Sherri Wilkins on her first creative break

Carling's Sherri Wilkins on her first creative break

The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.

Commercial Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

Features Read the complete September 2016 digital edition

Read the complete September 2016 digital edition

Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.

Legal/Regulatory Why the FDA's view of patient communication evolved over time

Why the FDA's view of patient communication evolved over time

The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.

Payers/Managed Markets Power to the payers: PBMs leave behind a trail of tiers

Power to the payers: PBMs leave behind a trail of tiers

When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.

Campaigns 30 years later, DTC's complicated past still hasn't deterred marketers

30 years later, DTC's complicated past still hasn't deterred marketers

Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.

Commercial 7 ways Viagra changed how drugs are marketed

7 ways Viagra changed how drugs are marketed

The inside story on a campaign for the ages, as told by the individuals who worked on it.

Campaigns Merck's creative archive tells an industry story

Merck's creative archive tells an industry story

Did you know that Norman Rockwell was a medical illustrator for Merck?

Commercial The provider gift ban: The day the tchotchkes died

The provider gift ban: The day the tchotchkes died

For some people in the industry ecosystem, the appeal of promo knickknacks endures.

Commercial How five therapies changed the course of pharma history

How five therapies changed the course of pharma history

And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.

At Work With WebMD's Leming on audience development and lessons from CNN.com

WebMD's Leming on audience development and lessons from CNN.com

The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.

Careers What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

Careers The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Sponsored Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Careers Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sponsored Data, Technology, and Medicine: How They Intersect

Data, Technology, and Medicine: How They Intersect

The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.

Commercial Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

Commercial Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

Commercial The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Commercial Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Commercial Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Pipeline Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Commercial Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Features Read the complete August 2016 digital edition

Read the complete August 2016 digital edition

Read about MM&M's inaugural Hall of Femme event and the rest of the MM&M August issue.

Payers/Managed Markets PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Features Read the complete July 2016 digital edition

Read the complete July 2016 digital edition

Read the 2016 Agency Issue in its entirety.

Sponsored Patient-Centricity: There's Always Room for Improvement

Patient-Centricity: There's Always Room for Improvement

It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.

Careers Christine Coyne on the moment with a male boss that influenced her career

Christine Coyne on the moment with a male boss that influenced her career

A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.

Sponsored The Story Behind the Story, Live From Cannes, Presented by McCann Health

The Story Behind the Story, Live From Cannes, Presented by McCann Health

McCann Health, the 2016 Lions Health Network of the Year, and Campaign invited top marketers and visionary artists to discuss creativity during this year's Lions Health festival.

Technology 8 ways for pharma to improve the way it uses Twitter

8 ways for pharma to improve the way it uses Twitter

Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.

Commercial Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.

Technology Healthcare marketers: Don't forget about the baby boomers

Healthcare marketers: Don't forget about the baby boomers

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

Pipeline CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Pipeline Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

Commercial As immuno-oncology therapies evolve, so will the marketing

As immuno-oncology therapies evolve, so will the marketing

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Corporate Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Features Read the complete June 2016 digital edition

Read the complete June 2016 digital edition

Read the 2016 June issue in its entirety.

Features 100 quotes: What they reveal about the state of healthcare advertising

100 quotes: What they reveal about the state of healthcare advertising

Visions, challenges, and advice: Here are 100 quotes from 100 agency leaders, compiled from the MM&M Agency Issue.

Agencies 3 questions for 5 of the agency world's leading executives

3 questions for 5 of the agency world's leading executives

Five executives from the industry's largest holding companies discuss their move away from the traditional network structure.

Agencies How the healthcare agency solar system evolved this year

How the healthcare agency solar system evolved this year

A number of mergers and acquisitions among healthcare agencies in 2015 and 2016 changed the landscape.

Agencies Revenues surge as agencies adapt to health-tech, payer trends

Revenues surge as agencies adapt to health-tech, payer trends

Healthcare agencies focus on freeing pharma brands from their collaboration cocoons to work with health tech companies, while squaring away access concerns.

Agencies At Work With: Kantar Health's Tom Haskell

At Work With: Kantar Health's Tom Haskell

The co-founder of Mapquest.com talks about his move from online mapping to healthcare, and what he likes most meeting with clients.

People Moves Digitas Health LifeBrands' Susan Manber on telling a healthy story

Digitas Health LifeBrands' Susan Manber on telling a healthy story

The chief planning officer of North America talks about strategy and how to tell an engaging health story.

Data/Analytics The CIO, reimagined for pharma

The CIO, reimagined for pharma

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Technology Pharma companies turn to wearables to improve R&D

Pharma companies turn to wearables to improve R&D

Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.

Features Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Sponsored The Patient Journey 2016: PDR

The Patient Journey 2016: PDR

Features Why Healthcare Needs "Mad Women"

Why Healthcare Needs "Mad Women"

Besides being the right thing to do, elevating woman leaders confers a competitive edge to companies, a fact confirmed by multiple studies.

Features Telehealth: Improving the customer experience but still an unknown for pharma

Telehealth: Improving the customer experience but still an unknown for pharma

Although telehealth is still in its early stages, it's building momentum — with good reason.

Commercial Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Commercial What do physicians think about biosimilars?

What do physicians think about biosimilars?

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Commercial Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Features Why are We Still Shortchanging Women in the Workplace?

Why are We Still Shortchanging Women in the Workplace?

Why would any CEO tolerate a corporate culture that holds people back?

OPINION

Email Newsletters